Two hypotheses were proposed: the first is that the broader inhibition of the EGFR family may improve the efficacy of EGFR-TKIs for NSCLC with EGFR mutation, and the second is that the broader inhibition of the EGFR family may attenuate T790M in cancer cells during relapse after EGFR-TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.